This publication serves as a useful resource for nuclear medicine physicians, radiologists, radiopharmacists, pharmacologists and other researchers engaged with radiolabelling of autologous products ...

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ...

Dr L J Salmon, North Sydney Orthopaedic and Sports Medicine Centre, 286 Pacific Hwy, Crows Nest, Sydney NSW 2065, Australia; lsalmon{at}nsosmc.com.au If you wish to ...

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

The goal of HCT is to cure an underlying malignancy or hematologic disorder. The procedure can be performed in an inpatient ...

The global cell therapy manufacturing market is poised for remarkable growth, with market size expected to reach USD 15,634.67 million by 2033, according to recent market projections. In 2023, the ...

The firm is discontinuing its CHIRON and THETIS trials after lackluster data and is planning for potential third-party deals and workforce layoffs.

Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...

The following is a summary of “Long-term outcomes of renal AL amyloidosis patients undergoing autologous stem cell ...

Dr. Edwards, a distinguished osteopathic physician, complements Dr. Sher’s medical expertise with his unique perspective and ...